S&P Futures
4,381.50 -93.25 (-2.08%) Dow Futures
33,992.00 -261.00 (-0.76%) Nasdaq Futures
14,308.00 -193.00 (-1.33%) Russell 2000 Futures
2,008.40 -23.30 (-1.15%) Crude Oil
undefined (0) Gold
1,841.10 -0.60 (-0.03%)
Rockwell Medical, Inc. (RMTI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.3930 |
| Open | 0.3800 |
| Bid | 0.3870 x 900 |
| Ask | 0.3900 x 800 |
| Day's Range | 0.3508 - 0.3889 |
| 52 Week Range | 0.3400 - 1.9800 |
| Volume | |
| Avg. Volume | 2,437,375 |
| Market Cap | 35.745M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3460 |
| Earnings Date | Mar 29, 2022 - Apr 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- GlobeNewswire
Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea
Two product forms of Triferic® are now approved in South KoreaWIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyr
- ACCESSWIRE
The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical
VANCOUVER, BC / ACCESSWIRE / January 14, 2022 / The Power Play by The Market Herald has announced the release of new interviews with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical discussing their latest press releases.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.
- Benzinga
Rockwell Medical Shares Surge On South Korean Approval For Iron Supplementation Therapy
Rockwell Medical Inc's (NASDAQ: RMTI) partner, Jeil Pharmaceutical Co Ltd, has received regulatory approval in South Korea for Triferic Injection for iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical has an exclusive license agreement with Jeil to commercialize Triferic in South Korea. Regarding the license, Rockwell Medical has received an upfront fee and will be eligible for milestone payments and roya
